Dry powder formulations of polynucleotide complexes

Details Dry powder formulations of polynucleotide complexes Dry powder formulations of polynucleotide complexes

1995-06-09

1998-09-22

Ketter, James

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 231, 536 245, 4351723, 424450, A61K 4800

Patent

active

058114068

ABSTRACT:
Polynucleotide complexes are stabilized by adding a cryoprotectant compound and lyophilizing the resulting formulation. The lyophilized formulations are milled or sieved into a dry powder formulation which may be used to deliver the polynucleotide complex. Delivery of the polynucleotide to a desired cell tissue is accomplished by contacting the tissue with the powder to rehydrate it. In a preferred embodiment, a dry powder formulation is used to transfer genetic information to the cells of the respiratory tract.

REFERENCES:
patent: 4766046 (1988-08-01), Abra et al.
Mennino, et al. 1988 Biotechniques vol. 6. No. 7. pp. 682-690 "Lipsome Mediated Gene Transfer".
Gura, T. 1995. Science vol. 270 pp. 575-577. "Antisense His Growing Pains".
Orkin, et al. Dec. 7, 1995. "Report and Recommendations of The Panel to Assess The NIH Investment in Research on Gene Therapy".

Affiliated with

Also associated with

Rating

Dry powder formulations of polynucleotide complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Dry powder formulations of polynucleotide complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dry powder formulations of polynucleotide complexes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1621878